866-997-4948 (US-Canada Toll Free)

Publications by Justpharmareports provide clear, comprehensive, up-to-date, practical information and analyses on pricing/ reimbursement and medicines’ distribution for the industry professional. Researched and written exclusively by Donald Macarthur, probably the world's most experienced author of reports on the global pharmaceutical business environment, with more than 70 major titles...

Show More

Publications by Justpharmareports provide clear, comprehensive, up-to-date, practical information and analyses on pricing/ reimbursement and medicines’ distribution for the industry professional. Researched and written exclusively by Donald Macarthur, probably the world's most experienced author of reports on the global pharmaceutical business environment, with more than 70 major titles over 25 years to his name, the detailed but readable texts will save $000s in consultants' fees alone.

Show Less
  • Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2013 Edition

    Oct 2013

    By JustPharmaReports.com

    Pharmaceutical

    208 Pages

    The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough to assure premium prices and special status in an era of budget...

    USD 2350View Report
  • Risk Sharing and Other Forms of Managed Entry Agreements for Medicines, Worldwide

    Feb 2013

    By JustPharmaReports.com

    Pharmaceutical

    94 Pages

    Managed entry agreements apply to an increasing number of new, innovative drugs in a growing number of markets. They are designed to share the risk between the manufacturer and the payer, consequent on uncertainties - usually at launch - about the product’s value (clinical- and cost-effectiveness), budget impact and/or utilisation to optimise performance, whilst at the same time...

    USD 1050View Report
  • Pharmaceutical Pricing & Distribution in Japan, 2012 Update

    Jun 2012

    By JustPharmaReports.com

    Pharmaceutical

    90 Pages

    No serious pharmaceutical company can afford to ignore Japan, a $120 billion market, the second-largest in the world. It remains a tough and highly competitive market to crack, however, with the environment for developing and marketing medicines dominated by price.  No new brand can be introduced without a yakka (reimbursement price) set by the  government....

    USD 1400View Report
  • Biosimilars: Current Situation & Future Prospects, Worldwide

    Mar 2012

    By JustPharmaReports.com

    Biomarkers

    135 Pages

    The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with the vast majority of leading originator brands in the global biologics market expected to lose some degree of protection by 2019. All major countries now make provision for an abbreviated biosimilar development and regulatory...

    USD 3000View Report
  • Pharmaceutical Pricing & Distribution in Japan, 2010 Update

    Oct 2011

    By JustPharmaReports.com

    Pharmaceutical

    60 Pages

    The author’s 2008 major title ‘Pharmaceutical Pricing & Distribution in Japan’ was described by PhRMA Japan as ‘a superb report…to understand Japan there is nothing better’. His new report packs all the essentials needed to optimise market access and life cycle management into 60 pages and offers tremendous value. Completely updated, it...

  • Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access Issues, 2011 Edition

    Jun 2011

    By JustPharmaReports.com

    Pharmaceutical

    143 Pages

    The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough to assure premium prices and special status in an era of budget...

    USD 2300View Report
  • Market Access Korea: Breaking into the Developed World's Fastest Growing Pharmaceutical Market

    Nov 2010

    By JustPharmaReports.com

    Pharmaceutical

    66 Pages

    South Korea as a country has been an economic success story and the origin of much cutting edge technology, but its pharmaceutical market can now also be given ‘Asian tiger’ status. The past four years have seen total sales growth of 15.6%, 13.5%, 12.4% and 13.8% respectively. IMS forecasts CAGR of 6.5% from 2010 through 2015, making Korea the fastest growing developed market...

    USD 1380View Report
  • Orphan Drugs in Asia-Pacific: From Designation to Pricing, Funding & Market Access

    Feb 2010

    By JustPharmaReports.com

    Pharmaceutical

    91 Pages

    A major new report Orphan Drugs in Asia-Pacific: From designation to pricing, funding and market access focuses on five developed markets in the region: Japan, South Korea, Taiwan, Singapore and Australia. Each has passed specific measures to promote the development, registration and/or commercialisation of rare disease treatments. Singapore’s Medicines (Orphan Drug) Exemption...

    USD 2320View Report